PRKDC and breast carcinoma: Interestingly, in preclinical models we have recently shown that BRCA1/BER deficient breast cancer cells are sensitive to treatment with ATM and DNA-PKcs treatment either alone or in combination with cisplatin chemotherapy [10] suggesting additional approaches besides PARP inhibitors for personalized strategy.